Drug · DIN 02521903
PADCEV
SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 19, 2025; first marketed December 20, 2021.
- Drug Identification Number (DIN)
- 02521903
- Company (DIN owner)
- Pfizer Canada UlcKirkland, Quebec, Canada
- Schedule
- Prescription; Schedule d
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Enfortumab vedotin L01FX13
- Class
- Human
- Record last updated
- July 31, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ENFORTUMAB VEDOTIN | 20 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 19, 2025: NOC 36036New Drug Submission (NDS) · Administrative – Changes in product ownership
- October 29, 2021: NOC 26950New Drug Submission (NDS)
Other DINs named PADCEV
- DIN 02521911 · Marketed